Introduction {#Sec1}
============

Weight gain remains a well recognized yet difficult to treat adverse effect of many anti-psychotic drugs. This problem is not new. It emerged with the introduction of the first- generation of antipsychotic drugs (FGAs) but was overshadowed by their propensity to cause extrapyramidal side effects and tardive dyskinesia. Only with the advent of second-generation antipsychotic drugs (SGAs) the perspective shifted from movement disorders toward weight gain as the dominant adverse effect. Weight gain is not just a concern *per se*. Cosmetically undesirable or even considered stigmatizing as it may be, the main concern about weight gain relates to the increased risk of metabolic syndrome, diabetes and cardiovascular disease which may result in a significant decrease in life expectancy. For instance, more than two thirds of people with schizophrenia die from coronary heart disease (CHD) as compared to about half of the unaffected population \[[@CR1]\]. And more than one third of patients treated with antipsychotic drugs develop metabolic syndrome \[[@CR2]••\]. Depending on age, up to 15% of patients with schizophrenia may develop type 2- diabetes mellitus and up to 70% may have elevated serum lipids \[[@CR2]••\].

The weight gain liabilities of antipsychotic drugs are partly associated with their ability to increase appetite. Yet, most behavioral interventions for weight control do not specifically target the control of appetite. Instead, most interventions are geared toward reduction of calorie intake through dieting, promotion of fruit and vegetable intake and calorie expenditure through exercise. However, such strategies tend to increase rather than reduce appetite.

Here we provide an overview of (1) the potential drivers of antipsychotic-induced increase in appetite and weight gain, (2) the results of commonly tried behavioral interventions in view of the underlying pathophysiology, (3) the potential of behavioral strategies specifically targeted at antipsychotic-mediated pharmacodynamic and neuroendocrine effects and 4) the role of illicit substance use on appetite.

Potential Drivers of Antipsychotic-Induced Weight Gain and Increased Appetite {#Sec2}
=============================================================================

Identifying Receptors Facilitating Weight Gain {#Sec3}
----------------------------------------------

Of the FGAs, low-potency phenothiazines such as chlorpromazine carry the highest risk of increasing weight. Chlorpromazine may even increase the risk of metabolic syndrome and type 2- diabetes \[[@CR3]\]. On the other hand, the risk of weight gain is relatively low with high-potency FGAs such as perphenazine, fluphenazine and haloperidol \[[@CR4]•, [@CR5]\]. Of the SGAs, clozapine and olanzapine are most likely to increase weight, appetite and to stimulate overeating. Both drugs also increase the risk of metabolic syndrome and type 2- diabetes. Quetiapine, risperidone, paliperidone, asenapine, iloperidone and sertindole can also increase weight but to a lesser extent. These drugs are currently not associated with an increased risk of metabolic syndrome. Ziprasidone, amisulpride and aripiprazole and possibly lurasidone belong to a third category of antipsychotic drugs in which the risk of weight gain and appetite increase tends to be low or negligible \[[@CR3], [@CR4]•, [@CR5], [@CR6]\].

Blockade of dopamine (D2 and D3), serotonin (5HT2c), muscarinic (M3) and histamine (H1) receptors have all been implicated to increase appetite \[[@CR4]•, [@CR5], [@CR7]--[@CR9]\]. Weight gain liability seems inversely correlated to the specificity of the receptor profile of the antipsychotic drugs; the more receptors targeted, the less specific the drug and the more likely weight gain. Thus it is the non-specificity of an individual drug rather than the categorization into FAGs and SAGs that predict weight gain liability or metabolic risk \[[@CR2]••\]. Nonetheless, even drugs antagonizing only dopamine receptors (amisulpride, pimozide, etc.) show at least some propensity for weight gain.

Understanding Determinants of Appetite and Weight Gain {#Sec4}
------------------------------------------------------

Antipsychotic-induced stimulation of appetite and weight gain is multifactorial. Pharmacological, genetic, environmental and social factors as well as gender contribute \[[@CR2]••, [@CR5]\]. In the absence of one clearly identifiable factor, identification of a single effective treatment becomes unlikely. Food intake is the result of finely balanced neuroendocrine factors. Some of these promote appetite and others satiety. There are short-acting factors such as ghrelin and cholecystokinin (CKK). There are also long acting factors, beyond the time frame of an individual meal, such as leptin and insulin \[[@CR4]•, [@CR7], [@CR10]--[@CR18], [@CR19]•\] (Table [1](#Tab1){ref-type="table"}). All these factors act on the hypothalamus stimulating either orexogenic neurons such as neuropeptide-Y (NP-Y) and agouti-related peptide (AGrP) or anorexic neurons such as the melanocortins \[[@CR19]•\]. Adenosine-monophosphate activated protein-kinase (AMPK), acts as a cellular energy sensor integrating many of the neuroendocrine functions to become *"a master regulator of eating behavior through its activity in the hypothalamus"* \[[@CR10]\]. Hypothalamic activity is under cognitive and emotional control of the brain though. Whereas the dopamine and endocannabioid system mediate the motivation to seek food, i.e.m "wanting", the opioid system mediates feelings of pleasure when eating, i.e., "liking" \[[@CR15]\]. Dopamine antagonists can influence these systems at the hypothalamic and cortical level, but their actions are not always as might be anticipated. This makes specific targeting through behavioral interventions difficult.Table 1Some factors regulating eating behaviorSubstanceOrgan of originMechanism of actionStimulating food intakeNPYHPTStimulates neurons triggering eating behavior \[[@CR7], [@CR10], [@CR11]\]. Stimulated by ghrelin. Inhibited by leptin \[[@CR10], [@CR12]\].AgRPHPTInhibits activity of neurons stimulating melanocortin via GABA. Melanocortin decrease eating behavior as outlined below \[[@CR7], [@CR10]\]. May ↓ thyroid function in the presence of MSH.MCHHPTFacilitates action of leptin. ↑ during fasting when leptin levels fall \[[@CR12]\].Projects into the cortex, the amygdala and the spinal cord.OrexinsHPTRegulates feeding behavior and the sleep wake cycle \[[@CR12]\]. Ensures food- seeking behavior after periods of fasting. Projects into the cortex, the amygdala and the spinal cord \[[@CR12]\].AMPKHPTIntracellular energy sensor acting on ATP concentration. Facilitates production of ATP by opening catabolic and closing anabolic pathways \[[@CR10], [@CR13]\]. If ATP ↑, AMPK inactive leading ↓ food intake. If ATP ↓, AMPK active leading to ↑ food intake \[[@CR10], [@CR13]\]. AMPK action may differ between cell systems within the HPT and between tissue types in the body \[[@CR13], [@CR14]\]. For instance, the anti-diabetic drug metformin inhibits AMPK in the HPT but stimulates it in the skeletal muscle \[[@CR13]\].GhrelinSTShort acting. ↑ eating when the stomach is empty \[[@CR10]\]. Stimulates AMPK, NYP and AgRP and inhibits melanocortin in the HPT \[[@CR7], [@CR13], [@CR14]\].May inhibit insulin release \[[@CR14]\]. Falls quickly when food is taken in \[[@CR10]\].Decreasing food intakeMelanocortin producing hormones including α-MSH and β-MSH.HPTBlock neurons stimulating eating behavior. Counteract NYP and AgRP \[[@CR7], [@CR10], [@CR12]\]. Stimulate cholinergic neurons in the spinal cord and thus fine-tune autonomic regulation of the sympathetic and parasympathetic system \[[@CR12]\]. α-MSH is an agonist for the MC4-R which regulates food intake. Regulates transcription of thyrotropin-releasing hormone jointly with leptin \[[@CR12]\]. MC4-R is a target for the development of weight-reducing drugs \[[@CR4]•\]. Involved in regulating the hypothalamo-pituitary-adrenal (HPA) axis \[[@CR12]\].BDNFHPTUnclear, may be stimulated by MC4-R in the ventromedial area of the HPT \[[@CR15]\]. May interact with leptin and insulin \[[@CR15]\].InsulinPANCLong-acting. Facilitates uptake of glucose in body tissues such as muscles and fat \[[@CR10]\]. Promotes energy expenditure. Inhibits hypothalamic AMPK, NPY and AgRP. May act synergistically with leptin \[[@CR10], [@CR16]\]. Obesity may cause insulin resistance meaning that less sugar is cleared from the blood. Insulin resistance is a matter of degree rather than nature \[[@CR17]\].LeptinMainly ATLong-acting Fat sensor feeding back the amount of triglycerides to the brain by acting on NPY, AgRP, melanocortin and MSH in the hypothalamus \[[@CR4]•, [@CR10], [@CR12]\].If leptin levels ↑ eating ↓. If leptin levels ↓ eating ↑ \[[@CR10]\]. Inhibits hypothalamic AMPK \[[@CR13], [@CR18]\]. May act synergistically with insulin \[[@CR16]\].Regulates transcription of thyrotropin-releasing hormone jointly with MSH \[[@CR12]\].Obesity may cause leptin resistance so that eating is not longer reduced when leptin levels are high \[[@CR15], [@CR19]•\].CKK, GLP-1, YY, PYY~3-36~, etc.SISignals a feeling of fullness and satiety \[[@CR10], [@CR19]•\]. CKK is short acting. CKK and GLP-1 may regulate meal size \[[@CR19]•\].Glucagon, amylin, etc.PANCAmylin may regulate meal size together with CKK and GLP-1 \[[@CR19]•\].AT: adipose tissue; AMPK: Adenosinemonophosphate activated protein kinase; AgRP: Agouti-related peptide; BDNF: Brain-derived neurotropic factor CKK: cholecystokinin; GLP-1: glucagon-like peptide-1; HPT: hypothalamus; MC4-R, melanocortin-4 receptor; MCH: Melanin-concentrating hormone; ɑ- and β-melanocyte stimulating hormone: ɑ-MSH and β-MSH; NPY: neuropeptide Y; PYY~3-36~oxyntomodulinpeptide YY; PANC: pancreas; SI: Small intestine; ST: stomach

For instance, antipsychotics with selective D2 and D3 receptor affinity such as aripiprazole, amisulpride and ziprasidone have a low risk of weight gain because blockade of hypothalamic D2 and D3 receptors increase reactivity to neuropeptide Y (NPY). This effect may be enhanced by 5HT2 and alpha 1adrenergic blockade \[[@CR11]\].

At a cortical level, dopamine and endorphins stimulate the reward system. Blunting of the reward system by dopamine blockade may lead to overeating in an attempt to overcome the anhedonic effect \[[@CR4]•, [@CR20]\]. Genetic variation may determine how well individual people can suppress eating \[[@CR4]•\]. Thus, individual ability to fine-tune the reward system may explain why selective D2 and D3 receptor blockade can cause weight gain in only some people.

Insulin tends to decrease eating behavior under normal conditions but hyperinsulinemia promotes weight gain \[[@CR16]\]. Treatment with insulin is also associated with weight gain. Hypoglycemia only occurs though if the insulin dose exceeds carbohydrate intake \[[@CR21]\]. The concept that low blood sugar levels, yet still in the normal range, induce craving for carbohydrates due to a hyper-secretion of insulin remains controversial \[[@CR19]•, [@CR22]\]. Regardless, the individual response to low-glycemic load diets may differ depending on ethnicity \[[@CR23]\]. Regarding the diabetogenic risk of some antipsychotics we note that insulin secretion is under muscarinic control and blockade of muscarinic (i.e., not nicotinic) receptors may lead to a compensatory over-stimulation of insulin until it becomes down regulated \[[@CR24]\]. Drugs with anti-muscarinic properties, such as clozapine, olanzapine, N-desalkylquetiapine are diabetogenic. But olanzapine has relatively low rates of anticholinergic adverse effects \[[@CR25]\] and neither demands the use of anticholinergics to counter extrapyramidal side effects *per se*. This hypothesis might also not hold if we adopted the alternative view that insulin resistance and metabolic syndrome was a consequence of a disorder of the fat metabolism due to inflammation of adipose tissue rather than a consequence of a dysregulated carbohydrate metabolism \[[@CR26]\].

Olanzapine and clozapine in particular are known to increase leptin \[[@CR27]\], but as a rise in leptin is in line with the fat stores this may be a consequence rather than a cause of weight gain. High leptin levels decrease appetite but as body-own leptin targets become reset people finally becoming leptin resistant and continue to overeat despite high leptin levels. Fasting will then invariably tilt the balance toward stimulating food intake as an evolutionary bias toward weight gain \[[@CR15]\].

The relationship between ghrelin, another potent stimulator of appetite, and SGAs appears more complex; short-term reductions of ghrelin seem to be followed by longer-term increases \[[@CR27]\]. Finally, SGAs linked to greater weight gain such as clozapine, olanzapine and quetiapine seem to stimulate adenosinemonophosphate activated protein kinase (AMPK) whereas risperidone, ziprasidone, haloperidol and aripiprazole do not. This AMPK stimulation is linked to H1 blockade \[[@CR8]\] making anti-histaminergic properties a prime risk factor for weight gain.

Behavioral Intervention for Control of Appetite and Weight Gain -- The Evidence {#Sec5}
===============================================================================

In view of the considerable impact many SGAs and even some FGAs have on the neuroendocrine system, the question arises whether or not behavioral interventions are effective in preventing or reducing weight gain. The systematic reviews and meta-analyses reviewed here seem to support this \[[@CR28]--[@CR34]\] (Table [2](#Tab2){ref-type="table"}). Both, prevention and the treatment of weight gain, may lead to weight loss of about 3 kg. This corresponds to a reduction of body mass index (BMI) of approximately one point. In most reviews, prevention led to slightly more weight loss than treatment \[[@CR28], [@CR29], [@CR31], [@CR32]\]. A whole array of interventions or combination of interventions may work, including psychological interventions, diet and exercise. Psychological interventions ranged from cognitive behavioral therapy (CBT), psycho-education, motivational interviewing to stress management. Such interventions were important but it remained unclear whether CBT or psycho-educational interventions yielded the better results \[[@CR28]--[@CR31]\]. Outpatient treatment may be superior to inpatient treatment, but tight calorie restriction in individual cases of extreme obesity may nevertheless be best conducted under inpatient conditions \[[@CR33], [@CR34]\]. In general, it was difficult to unravel the particular contribution of each treatment component because they tended to overlap. Programs combining all three, diet, exercise and psychological, interventions may work best \[[@CR29]\].Table 2Effectiveness of behavioral interventions for appetite and weight control -- evidence from systematic reviews and meta-analyses during the last ten yearsStudyInterventions identified as potentially successfulEffect sizeBonfioli E et al. 2012\* \[[@CR28]\]CBT and psycho-education, diet, exercise. Programs including all three components highest impact. Similar effects in pts with first episode or chronic psychosis.Pooled ES for BMIT: -0.86; 95% CI: -1.38 to -0.33P: -1.09; 95% CI: -1.51 to -0.68TOT: -0.98; 95% CI: -1.31 to -0.65Caemmerer et al. 2012 \[[@CR29]\]Nutritional and/or exercise \> CBT, but effectiveness of individual components difficult to judge since programs tended to overlap. Effect only seen in out-patient but not in in-patient or mixed trials.Pooled ES for WGT in kgT: -3.04; 95% CI: -4.39 to -1.68P: -3.23; 95% CI: -4.41 to -2.04Total: -3.12; 95% CI: -4.03 to -2.21Pooled ES for BMI:TOT: -0.94; 95% CI: -1.45 to -0.43Gabriele et al. 2009 \[[@CR30]\]T: Diet, exercise and psychological support. Increased length of intervention may lead to additional weight loss.ES for WGT in kgP: Counseling on diet and exercise may decrease the rate of weight gain but not prevent it all together.T: mean: -2.63; range: -3.20 to - .40P: mean: 2.44; range: 0.37 to 4.95Alvarez-Jiminez et al. 2008 \[[@CR31]\]CBT and nutritional counseling, only one study tested a diet and exercise program. Individual superior to group interventions. No significant difference between counseling and CBT, prevention and treatment, pts with recent onset of schizophrenia and chronic schizophrenia. One trial pointed towards effectiveness of prevention in pts with recent onset. OP interventions more effective than IP or mixed sample interventions.Pooled ES for WGT in kg:Metformin outperformed behavioral intervention.T: -2.32; 95% CI: -3.10 to -1.54Metformin + behavioral intervention outperformed metformin.P: -3.05; 95%, CI: -4.16 to -1.94TOT: -2.56; 95% CI: -3.20 to -1.92Pooled ES for BMI:TOT: -0.91; 95% CI:-1.13 to -0.68Faulkner et al. 2007 \[[@CR32]\]CBTPooled ES for WGT in kg:T: -1.69; 95% CI: -2.77 to -0.61P: -4.87; 95% CI: -7.11 to -2.64Pooled effect sizes BMI:T: -0.66; 95% CI: -1.06 to -0.25P: -1.52; 95% CI: -2.25 to -0.79Faulkner et al. 2003 \[[@CR33]\]Weight loss difficult but not impossible. Caloric restriction, reinforcement and adjunct CBT. Caloric restriction may work best for IP. Exercise could not be evaluated.Range WGT in kg: -28.57 to 0.4Werneke et al. 2003 \[[@CR34]\]Evidence remains limited. Calorie restriction in an IP setting, but significant deterioration of mental state can occur. Structured counseling and CBT. Life-style counseling and reinforcement.Range (excluding case reports) WGT in kg: -5.9 to - 0.6, but results compared with controls NS in most of the included studies.CBT: cognitive behavioral therapy; m: month; ES: effect size; IP: inpatients; MA: meta-analysis; P: prevention; OP: outpatients; pt: patient; NS: not significant; SR: systematic review; T: treatment; TPT: total; WGT: weight; wk: week; y: year\*Provisional version

Although these results are encouraging it appears that weight gain associated with to antipsychotic treatment tends to be greater than weight loss achieved through subsequent behavioral interventions \[[@CR35]•, [@CR36]\]. This highlights the importance of monitoring weight and preventing weight gain in the first place. Also, significant anti-psychotic induced weight gain tends to occur early in treatment \[[@CR35]•--[@CR37]\]. Weight may then gradually increase over several years and only plateau after more than three and a half years after commencement of antipsychotics \[[@CR35]•, [@CR38], [@CR39]\]. One study though, following up 113 patients who received life style advice in a group setting for 8 years, found that substantial weight loss could be achieved over long periods of time. However, this study had no control group and about 70% of the patients had dropped out of the program within two years \[[@CR40]\].

We currently do not know whether weight loss can be sustained over longer periods of time or if in the end most patients, like the rest of the population, just re-gain weight or cycle between weight gain and weight loss \[[@CR41]\]. Weight control measures for people taking antipsychotics are a long-term commitment to be reconciled with limited health care resources. At present, it remains unclear whether individual booster sessions could suffice to maintain the benefit. It follows that whenever possible, it would be best to opt for an antipsychotic with low weight gain liabilities rather than to rely on a behavioral intervention to control weight. Once weight gain has occurred switching to an antipsychotic with less or low weight gain liabilities also becomes an option \[[@CR42]--[@CR45]\]. Antipsychotic polypharmacy can also increase the risk \[[@CR46]\], but the risk may depend on the combination chosen \[[@CR47]•\].

Behavioral Strategies in Light of Antipsychotic-Mediated Pharmacodynamic and Neuroendocrine Effects {#Sec6}
===================================================================================================

Behavioral interventions can be used to curtail anti-psychotic induced weight gain. The evidence for their effectiveness in daily clinical practice remains limited though, possibly because current behavioral interventions do not have specific pharmacodynamic or neuroendocrine treatment targets. Now the question arises as to how we can augment effectiveness by using interventions specifically countering mechanisms of weight gain. From our review of factors regulating appetite, we can identify four such potential strategies:Using diets which do not increase appetite to reduce craving for carbohydrates and fat.Countering thirst as an anticholinergic side-effect.Discouraging cannabis use.Adding metformin to a behavioral intervention.

Using Diets Which Do not Increase Appetite {#Sec7}
------------------------------------------

Successful dietary strategies depend on calorie restriction. Although it makes intuitively sense to reduce calorie intake this may turn into an uphill struggle for patients since calorie restriction invariably leads to increased appetite. Loss of fat mass will trigger a decrease in leptin. This results in an increase of appetite in an attempt to restore the fat mass. At the same time, ghrelin levels inducing appetite may increase \[[@CR19]•\]. In consequence, diets less likely to stimulate appetite despite energy restriction may lead to better treatment outcomes.

Patients treated with antipsychotics stimulating appetite and inducing cravings for carbohydrates and fat \[[@CR48]\] may not be able to adhere to calorie restriction. Unless there is insight into mental illness and the subjective benefits of antipsychotic treatment are so convincing that they offset undesirable weight gain, patients are at risk of abandoning their antipsychotic treatment \[[@CR49]\]. Indeed patients receiving such antipsychotics are faced with a paradox. On the one hand they are given drugs increasing their appetite. On the other hand they are told to decrease eating. Hence, diets not restricting calories and not increasing appetite are the obvious answer. But such diets are not easy to come by.

Low Carbohydrate High Fat Diet {#Sec8}
------------------------------

The prototype of a dietary regimen not restricting calories is the low carbohydrate-high fat (LCHF), Atkins or ketogenic diet \[[@CR50]•\]. The LCHF diet restricts carbohydrates but freely allows protein and fat. The LCHF is as effective as conventional diets at reducing weight and improving the lipid profile by raising "healthy" high-density lipoprotein cholesterol. Less consistently reported are reductions in blood sugar and serum triglycerides \[[@CR51]--[@CR56]\]. The LCHF diet mimics a state of starvation in that it enforces the use of ketone bodies as the result as the main energy supply. Essentially, ketone bodies, a result from the break down of free fatty acids, are used instead of glucose as obtained from carbohydrate metabolism. As carbohydrates in excess of 100 g per day will prevent ketosis the intake must lie below this threshold. Commonly, LCHF diets restrict carbohydrate to 30 g per day. Some extreme approaches only allow 10 g.

Whether the LCHF diet works because of carbohydrate restriction remains debated. Sacks et al. have shown that targeting *any* of the macronutrients may promote weight loss \[[@CR57]\]. As in most Western diets 45-50% of calories stem from carbohydrates and 35% from fat targeting carbohydrates seems more promising. Also, it is now well known that proteins suppress appetite \[[@CR58]\]. Notably, ketone bodies in their own right may suppress feelings of hunger; this effect may take about three days to materialize \[[@CR59]\]. However, hunger and appetite may be suppressed right from the onset of such a diet because the gastro-intestinal peptides can still signal "fullness" in the absence of calorie restriction.

However, the LHCF diet is highly unpalatable making long- term compliance difficult. Weight regain appears most likely when people re-introduce carbohydrates and then end up on a diet which is both high in fats and carbohydrates \[[@CR56]\], the worst of both worlds \[[@CR60]••\]. Excessive protein intake may carry health risks but the relationship between such risks and common multifactorial diseases is complex and hence difficult to assess \[[@CR61]\]. Recently, a large cohort study reported an increase of cardiovascular disease \[[@CR62]•\]. The World Health Organization estimates that an intake of twice the recommended intake may be safe in *"physically active individuals consuming average mixed diets who would otherwise be identified as having healthy lifestyles"* \[[@CR61]\]. Suffice it to say that many patients taking antipsychotics do not fall into this category; their safe upper level of intake could be lower. Very high protein intakes can also influence the metabolism and excretion of drugs. Finally, low carbohydrate intake may adversely affect mood and increase irritability \[[@CR63]\]. This could limit the applicability of the LCHF in people with severe mental health problems.

Other Options for Cutting Glycemic Load {#Sec9}
---------------------------------------

Possible --non ketogenic- alternative options to cut glycemic load include the Mediterranean or the glycemic index (GI) diet. The Mediterranean diet based on a high intake of fiber and mono-saturated fats such as olive oil, decreases glycemic load through its higher fats contents \[[@CR51], [@CR64], [@CR65]\]. The GI diet reduces intake of foods with a high glycemic index (foods easily broken down to glucose). Such foods include refined - white- grain products and products in which sugar is added during processing or preparation \[[@CR66]\]. Both dietary approaches tilt the balance from processed and highly refined to freshly prepared food irrespective of its carbohydrate and fat content.

The Evidence for Carbohydrate-Reducing Diets {#Sec10}
--------------------------------------------

Most people taking antipsychotics will have difficulties coping with diets requiring a calorie deficit. This provides a rationale for focusing on diets cutting the glycemic load especially since carbohydrate provides most of the food energy. Such specific dietary strategies have however received little attention from researchers \[[@CR67]\].

The LCHF, the most extreme way to reduce appetite, has not been tested at all. Clinicians and researchers may believe that such diets are either too complex to follow or are detrimental to mental health. Also eating large amounts of fat to loose weight seems counter-intuitive. In practice though, most LCHF diets do not contain larger amounts of fat than normally consumed \[[@CR55]\]; the proportion of energy derived from fat is increased because of the reduced contribution from carbohydrates. Technically, a low-carbohydrate diet should not pose a greater challenge than a low fat diet or a calorie restricted diet. Intriguingly, the ketogenic diet has occasionally been reported to improve psychotic symptoms in patients suffering from schizophrenia \[[@CR68], [@CR69]\]. Given that the ketogenic diet can be used to treat certain form of epilepsies such as myoclonic epilepsy \[[@CR70]\] and may even be of value for some patients suffering from autism \[[@CR71]\], the question arises whether this diet could be of some benefit in other neuro-developmental and degenerative brain disorders \[[@CR72]\] including schizophrenia.

Countering Thirst as an Anticholinergic Side Effect {#Sec11}
---------------------------------------------------

Some antipsychotics with high weight gain liabilities have anticholinergic effects. Thus, we can expect dry mouth with an increased urge to take fluids in compensation to occur. Notably, clozapine can cause both dry mouth and hypersalivation possibly due to differential effects at adrenergic and muscarinic receptors \[[@CR73], [@CR74]\]. Such effects could lead to increased salivation during sleep and rest but decreased salivation during meals \[[@CR73]\]. Patients experiencing dry mouth often increase their fluid intake. At the same time, they may increase their calorie intake if choosing drinks containing sugar such as many sodas and fruit juices.

Unsurprisingly, sugar-sweetened sodas are a major contributor to obesity \[[@CR60]••, [@CR75]•\]. Fruit juices usually get better press since perceived as rich in vitamins and hence healthy, but juices contain a lot of sugar and as a result are quite high in calories. For example one 300 ml glass of apple juice contains about 10% sugar providing about 114 kcal, about the same as three apples \[[@CR76]\]. Recent trials have shown that replacing sugar-sweetened beverages by artificially sweetened drinks can indeed reduce weight gain \[[@CR77]••, [@CR78]••\]. However, as with so many interventions health benefits may wane over time \[[@CR78]••\].

Milk irrespective of its fat contents has not been associated with weight gain \[[@CR60]••\]. Dairy products have a role in energy-restricted diets in helping maintaining nutritional adequacy but have no specific weight reducing properties \[[@CR79]•\]. Reduced fat milk and yoghurt have fewer calories but most of the nutritional value provided by full-fat milk. In the UK, dairy intake including milk has shown to be inversely associated with the consumption of sugar-sweetened drinks in low-income families \[[@CR80], [@CR81]\]. But ultimately fluid intakes are best met by increased water consumption. In summary, dietary counseling should include advice on how to drink well to reduce calorie-intake \[[@CR56]\]. There is clearly a need for a randomized controlled trial in this area.

Discouraging Cannabis Use {#Sec12}
-------------------------

Cannabis use is common all over the world and according to global estimates, 2.8-4.5% of the entire world population used cannabis at least once in the year 2009 \[[@CR82]\]. Cannabis use is associated with an increased risk of psychotic illness and conversely, individuals with psychotic illness are more likely to use cannabis \[[@CR82]\] although the estimates vary. Between, 20 and 50% of all patients with psychotic illness may consume cannabis and the trend is increasing \[[@CR82]--[@CR86]\]. As the endocannabioid system is linked to increased appetite and cannabioid receptor antagonists can induce weight loss \[[@CR15]\] cannabis consumption will most likely potentiate antipsychotic-associated weight gain. As the prevalence of cannabis use in people suffering from psychosis is so high, the contribution of cannabis to weight gain in this population is likely to be significant. Surprisingly, this link between cannabis and weight gain remains largely ignored at present. However, one study of patients admitted to a psychiatric intensive care unit found that patients using cannabis had higher glucose levels at admission. They were also significantly more likely to gain weight during their hospital stay \[[@CR87]\], presumably coinciding with the initiation or re-initiation of antipsychotic treatment.

Adding Metformin to a Behavioral Intervention {#Sec13}
---------------------------------------------

Metformin is a bigunanide anti-diabetic drug. Metformin is also used for the treatment of polycystic ovaries, an endocrine condition in women leading to testosterone overproduction linked to insulin resistance. Metformin activates AMPK peripherally in the liver and there prevents gluconeogenesis \[[@CR10]\]. The absence of weight gain implies that metformin does not act on AMPK centrally in the hypothalamus. Several systematic reviews and meta-analyses have been conducted suggesting that metformin can lead to partial reversal of antipsychotic-associated weight gain and improvement of the metabolic profile \[[@CR88]••\]. However, most trials tended to be small and of shorter duration. The emerging evidence suggested that the effect of metformin may be greatest in younger patients who receive antipsychotics for the first time and who show a tendency toward rapid weight gain and metabolic problems \[[@CR88]••, [@CR89]\]. The most recent trial not yet included in any systematic review or meta-analysis was conducted in women aged between 18 and 40 years suffering from a first episode of schizophrenia and antipsychotic-induced amenorrhea. In this study, metformin was effective facilitating weight loss, improving insulin resistance and restoring menstruation \[[@CR90]•\]. However up to date, only one study evaluated metformin head to head against a behavioral intervention. All 128 patients in this trial had experienced a first episode of schizophrenia and gained more than 10% weight after commencement of drug treatment. In this trial, metformin was superior to the behavioral intervention, but a combination of both was superior to metformin alone \[[@CR91]\]. In consequence, early intervention with both behavioral strategies and metformin may well be indicated in people with mental illness who are about to start anti-psychotic treatment or who are undergoing treatment and have experienced significant weight gain \[[@CR92], [@CR93]\].

Conclusion {#Sec14}
==========

Behavioral interventions are important for the prevention and management of antipsychotic-induced weight gain, yet evidence for their efficacy remains limited. As expected, interventions to prevent weight gain seem slightly more effective than strategies to treat weight gain; weight gain, once it has occurred, is difficult to reverse fully. The results indicate that whenever possible, antipsychotics associated with weight gain should be avoided in the first place and that patients who have experienced weight gain should be offered a less offending agent. But often, this may not be feasible when patients have responded well to a particular agent and the risks and benefits for mental and physical health have to be weighed up in each individual case.

It should come as no surprise that the scope of successful behavioral interventions is limited. We find ourselves in the midst of an obesity epidemic in large parts of the industrialized world \[[@CR75]•, [@CR94]\] and weight interventions such as diet and exercise have only yielded short rather than long term health improvements in the general population without significant mental health problems \[[@CR94]\]. How much less likely are people to succeed who experience acute stress or lack of drive and motivation due to a psychotic illness and who at the same time require medication increasing their appetite and weight? We already know that these patients require long-term psychological support when embarking on weight control program. Formulating specific strategies directly acting on the biochemical mechanisms of anti-psychotic induced weight gain may increase the success of behavioral programs. In our review we identified four such strategies. Of these, discouraging consumptions of sugar-sweetened drinks and cannabis are uncontroversial but continue to lack systematic study. The argument for adding metformin to a behavioral intervention is becoming more compelling particularly in young people. The ketogenic diet is certainly the most controversial approach discussed in our review. Surprisingly though there is a possibility that this diet may even yield some mental health benefits and hence be of value in selected individuals. In view of our currently rather limited treatment repertoire it seems timely systematically to explore such more specific, novel and sometimes more extreme options.
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